Co-Overexpression of Cyclooxygenase-2 and Microsomal Prostaglandin E Synthase-1 Adversely Affects the Postoperative Survival in Non-small Cell Lung Cancer

Slides:

Advertisements

Similar presentations

Lung Adenocarcinoma with Ipsilateral Breast Metastasis: A Simple Coincidence? Hsu-Ching Huang, MD, Jen-Fan Hang, MD, Mei-Han Wu, MD, Teh-Ying Chou, MD,

Advertisements

Su K. Metcalfe, MD, MPH, Michael T

Immunohistochemical analysis of epidermal growth factor receptor family members in stage I non-small cell lung cancer Wu-Wei Lai, MD, Fen-Fen Chen, MD,

Outcomes of Primary Squamous Cell Carcinoma of Major Salivary Glands Treated by Surgery With or Without Postoperative Radiotherapy Lina Wang, MD, Hao.

Clinical and the Prognostic Characteristics of Lung Adenocarcinoma Patients with ROS1 Fusion in Comparison with Other Driver Mutations in East Asian Populations

Radiation Therapy for Invasive Breast Cancer Increases the Risk of Second Primary Lung Cancer: A Nationwide Population-Based Cohort Analysis Yi-Jhih.

Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor,

Comprehensive Pathological Analyses in Lung Squamous Cell Carcinoma: Single Cell Invasion, Nuclear Diameter, and Tumor Budding Are Independent Prognostic.

Factors leading to tracheobronchial self-expandable metallic stent fracture Fu-Tsai Chung, MD, Shu-Min Lin, MD, Hao-Cheng Chen, MD, Chun-Liang Chou, MD,

Deregulation of SLIT2-Mediated Cdc42 Activity Is Associated with Esophageal Cancer Metastasis and Poor Prognosis Ruo-Chia Tseng, PhD, Jia-Ming Chang,

High Expression of PHGDH Predicts Poor Prognosis in Non–Small Cell Lung Cancer Jinhong Zhu, Jianqun Ma, Xudong Wang, Tianjiao Ma, Shu Zhang, Wei Wang,

AZGP1 Autoantibody Predicts Survival and Histone Deacetylase Inhibitors Increase Expression in Lung Adenocarcinoma Daniel L. Albertus, BS, Christopher.

Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non–Small Cell Lung Cancer: A Randomized, Double-Blind,

Prognostic Significance of PD-L1 in Patients with Non–Small Cell Lung Cancer: A Large Cohort Study of Surgically Resected Cases Jong-Mu Sun, MD, Wei.

Comparison of 22C3 PD-L1 Expression between Surgically Resected Specimens and Paired Tissue Microarrays in Non–Small Cell Lung Cancer Chao Li, MD, PhD,

P63 and p73 Isoform Expression in Non-small Cell Lung Cancer and Corresponding Morphological Normal Lung Tissue Marco Lo Iacono, PhD, Valentina Monica,

Negative Thyroid Transcription Factor 1 Expression Defines an Unfavorable Subgroup of Lung Adenocarcinomas Yiliang Zhang, MD, Rui Wang, MD, PhD, Yuan.

Interleukin-17 and Prostaglandin E2 Are Involved in Formation of an M2 Macrophage- Dominant Microenvironment in Lung Cancer Lunxu Liu, MD, PhD, Dongxia.

Prognostic Significance of TAZ Expression in Resected Non-Small Cell Lung Cancer Mian Xie, MD, PhD, Li Zhang, MD, Chao-Sheng He, MD, Jin-Hui Hou, MD,

The role of mitochondrial DNA alterations in esophageal squamous cell carcinomas Chen-Sung Lin, MD, Shi-Chuan Chang, MD, PhD, Liang-Shun Wang, MD, Teh-Ying.

Osteopontin Combined With CD44v6, a Novel Prognostic Biomarker in Non-Small Cell Lung Cancer Undergoing Curative Resection Bing-sheng Sun, MD, PhD, Yue.

Thyroid Transcription Factor-1 Amplification and Expressions in Lung Adenocarcinoma Tissues and Pleural Effusions Predict Patient Survival and Prognosis

Postchemoradiotherapy Pathologic Stage Classified by the American Joint Committee on the Cancer Staging System Predicts Prognosis of Patients with Locally.

Membrane Carbonic Anhydrase IX Expression and Relapse Risk in Resected Stage I–II Non–Small-Cell Lung Cancer David J. Stewart, MD, Maria I. Nunez, MD,

Prognostic Variables in Thoracic Esophageal Squamous Cell Carcinoma

Osteopontin-Expressing Macrophages in Non-Small Cell Lung Cancer Predict Survival Yue Li, MD, Bing-sheng Sun, MD, PhD, Baoxiang Pei, MD, Chen-guang Li,

Prognostic Factors in Completely Resected Node-Negative Lung Adenocarcinoma of 3 cm or Smaller Jung-Jyh Hung, MD, PhD, Yi-Chen Yeh, MD, Yu-Chung Wu,

Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.

Samuel J. Wang, MD, PhD, C David Fuller, MD, Charles R. Thomas, MD

Deregulated p21WAF1 Overexpression Impacts Survival of Surgically Resected Esophageal Squamous Cell Carcinoma Patients Yih-Gang Goan, MD, Hon-Ki Hsu,

Aberrant Wnt1/β-Catenin Expression is an Independent Poor Prognostic Marker of Non- small Cell Lung Cancer After Surgery Xianhua Xu, MD, Ping-Li Sun,

Potential Role of Platelet-Derived Growth Factor Receptor Inhibition Using Imatinib in Combination with Docetaxel in the Treatment of Recurrent Non-small.

Predictors of Death, Local Recurrence, and Distant Metastasis in Completely Resected Pathological Stage-I Non–Small-Cell Lung Cancer Jung-Jyh Hung, MD,

The Oncofetal Protein IMP3: A Useful Marker to Predict Poor Clinical Outcome in Neuroendocrine Tumors of the Lung Alessandro Del Gobbo, MD, Valentina.

Interstitial tumor-associated macrophages combined with tumor-derived colony- stimulating factor-1 and interleukin-6, a novel prognostic biomarker in non–small.

Effusion Immunocytochemistry as an Alternative Approach for the Selection of First-Line Targeted Therapy in Advanced Lung Adenocarcinoma Tzu-Hsiu Tsai,

Lung Cancer and Prognosis in Taiwan: A Population-Based Cancer Registry Bing-Yen Wang, MD, Jing-Yang Huang, Ching-Yuan Cheng, MD, Ching-Hsiung Lin, MD,

Impact of Positive Nodal Metastases in Patients with Thymic Carcinoma and Thymic Neuroendocrine Tumors Benny Weksler, MD, Anthony Holden, MD, Jennifer.

Expression of Nuclear Factor-κB and Its Clinical Significance in Nonsmall-Cell Lung Cancer Zhenfa Zhang, MD, Jianqun Ma, MD, Ni Li, PhD, Nan Sun, MD,

Elizabeth B. Gottlin, PhD, Rex C. Bentley, MD, Michael J

Comparison of the 6th and 7th Editions of the American Joint Committee on Cancer Tumor-Node-Metastasis Staging System in Patients With Resected Esophageal.

Loss of CRNN expression is associated with advanced tumor stage and poor survival in patients with esophageal squamous cell carcinoma Po-Kuei Hsu, MD,

Tumor-Infiltrating Foxp3+ Regulatory T Cells are Correlated with Cyclooxygenase-2 Expression and are Associated with Recurrence in Resected Non-small.

Reduced membranous β-catenin protein expression is associated with metastasis and poor prognosis in squamous cell carcinoma of the esophagus Po-Kuei.

The Prognostic Value of the Number of Negative Lymph Nodes in Esophageal Cancer Patients After Transthoracic Resection Po-Kuei Hsu, MD, Chien-Sheng Huang,

Extratumoral Vascular Invasion Is a Significant Prognostic Indicator and a Predicting Factor of Distant Metastasis in Non-small Cell Lung Cancer Yoshihisa.

A Comprehensive Analysis of p16 Expression, Gene Status, and Promoter Hypermethylation In Surgically Resected Non-small Cell Lung Carcinomas William.

Thoracoscopic Lobectomy Produces Long-Term Survival Similar to That with Open Lobectomy in Cases of Non–Small Cell Lung Carcinoma: A Propensity-Matched.

Phase II Randomized Trial of Erlotinib or Vinorelbine in Chemonaive, Advanced, Non- small Cell Lung Cancer Patients Aged 70 Years or Older Yuh-Min Chen,

Immunohistochemical analysis of epidermal growth factor receptor family members in stage I non-small cell lung cancer Wu-Wei Lai, MD, Fen-Fen Chen, MD,

Expression and Mutational Status of c-kit in Thymic Epithelial Tumors

ALK Translocation in Non-small Cell Lung Cancer with Adenocarcinoma and Squamous Cell Carcinoma Markers Samuel J. Klempner, MD, David W. Cohen, MD, Daniel.

MET Expression Plays Differing Roles in Non–Small-Cell Lung Cancer Patients with or without EGFR Mutation Ling Huang, MS, She-Juan An, PhD, Zhi-Hong.

High Expression of p300 Has an Unfavorable Impact on Survival in Resectable Esophageal Squamous Cell Carcinoma Yong Li, MD, Hao-Xian Yang, MD, Rong-Zhen.

Use of MicroRNA Expression Levels to Predict Outcomes in Resected Stage I Non- small Cell Lung Cancer Eric Duncavage, MD, Boone Goodgame, MD, Ananth Sezhiyan,

Tumor-Stroma Ratio Is an Independent Predictor for Survival in Esophageal Squamous Cell Carcinoma kai Wang, MD, Wei Ma, MD, Jianbo Wang, MD, Liang Yu,

Clinical and the Prognostic Characteristics of Lung Adenocarcinoma Patients with ROS1 Fusion in Comparison with Other Driver Mutations in East Asian Populations

Epidermal Growth Factor Receptor Mutation Status in Stage I Lung Adenocarcinoma with Different Image Patterns Kuo-Hsuan Hsu, MD, Kun-Chieh Chen, MD,

Peripheral Direct Adjacent Lobe Invasion Non-small Cell Lung Cancer Has a Similar Survival to That of Parietal Pleural Invasion T3 Disease Hao-Xian Yang,

Different Efficacies of Erlotinib and Gefitinib in Taiwanese Patients with Advanced Non- small Cell Lung Cancer: A Retrospective Multicenter Study Wen-Chien.

Comprehensive Pathological Analyses in Lung Squamous Cell Carcinoma: Single Cell Invasion, Nuclear Diameter, and Tumor Budding Are Independent Prognostic.

Thymidylate Synthase Protein Expression by IHC and Gene Copy Number by SISH Correlate and Show Great Variability in Non–Small Cell Lung Cancer Murry.

Neuronatin Expression and Its Clinicopathological Significance in Pulmonary Non-small Cell Carcinoma Teruhito Uchihara, MD, Chigusa Okubo, MS, Ryota.

Bcl-2-Like Protein 11 Deletion Polymorphism Predicts Survival in Advanced Non–Small- Cell Lung Cancer Jih-Hsiang Lee, MD, Yu-Lin Lin, MD, Wei-Hsun Hsu,

Effect of Formalin Fixation on Tumor Size Determination in Stage I Non-Small Cell Lung Cancer Po-Kuei Hsu, MD, Hsu-Chih Huang, MD, Chih-Cheng Hsieh,

Clinicopathologic significance of cyclooxygenase-2 overexpression in esophageal squamous cell carcinoma Kuang-Tai Kuo, MD, Kuan-Chih Chow, PhD, Yu-Chung.

Survival Benefits of Postoperative Chemoradiation for Lymph Node–Positive Esophageal Squamous Cell Carcinoma Po-Kuei Hsu, MD, Chien-Sheng Huang, MD,

Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.

Time Trends of Surgical Outcome in Patients with Non-small Cell Lung Cancer Takeshi Hanagiri, MD, PhD, Tetsuro Baba, MD, PhD, Tetsuya So, MD, PhD, Manabu.

Postchemoradiotherapy Pathologic Stage Classified by the American Joint Committee on the Cancer Staging System Predicts Prognosis of Patients with Locally.

Presentation transcript:

Co-Overexpression of Cyclooxygenase-2 and Microsomal Prostaglandin E Synthase-1 Adversely Affects the Postoperative Survival in Non-small Cell Lung Cancer Yu-Chung Wu, MD, Li-Jen Su, PhD, Hao-Wei Wang, MD, Chien-Fu Jeff Lin, MD, PhD, Wen-Hu Hsu, MD, Teh-Ying Chou, MD, PhD, Chi- Ying F. Huang, PhD, Chia-Li Lu, MS, Chung-Tsen Hsueh, MD, PhD Journal of Thoracic Oncology Volume 5, Issue 8, Pages 1167-1174 (August 2010) DOI: 10.1097/JTO.0b013e3181e2f4f5 Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Western blot analysis of cyclooxygenase (COX)-2 and microsomal prostaglandin E synthase (mPGES)-1 in 79 patients with tumor and nontumor matched tissues. A, Representative Western blotting of adjacent normal (N)-tumor (T) matched tissues from five subjects. Ponceau S staining was used as a loading control. B, Boxplot showing the semiquantitative results of the COX-2 and mPGES-1 protein levels (in arbitrary densitometry units) in 79 patients with normal-tumor matched tissues. The bottom of each box is the 25th percentile; the top is the 75th percentile; and the band in the middle is the 50th percentile. The whiskers represent the minimum and maximum of all the data. Paired Student t test was used to compare between tumor and nontumor samples. Journal of Thoracic Oncology 2010 5, 1167-1174DOI: (10.1097/JTO.0b013e3181e2f4f5) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 Representative results of cyclooxygenase (COX)-2 (A and C) and microsomal prostaglandin E synthase (mPGES)-1 (B and D) expressed on tissue sections of lung squamous-cell carcinoma (A and B) and adenocarcinoma (C and D) by immunohistochemistry. If Western blotting results showed co-expression of COX-2 and mPGES-1, immunohistochemistry was performed to confirm their localizations. Diffuse cytoplasmic immunoreactivity for COX-2 and mPGES-1 were observed in the cancer cells. Brown indicates positive staining of COX-2 and mPGES-1; blue indicates counterstaining with hematoxylin (original magnification, ×200). Journal of Thoracic Oncology 2010 5, 1167-1174DOI: (10.1097/JTO.0b013e3181e2f4f5) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 3 Kaplan-Meier analysis showing cumulative overall survival (A) and disease-free survival (B) with regard to the co-expressed effects of cyclooxygenase (COX)-2 and microsomal prostaglandin E synthase (mPGES)-1. A significant difference in overall survival and disease-free survival was observed between patients with co-expression and patients without co-expression (p = 0.045 and 0.029, respectively, by multivariable Cox proportional hazard regression analysis). Journal of Thoracic Oncology 2010 5, 1167-1174DOI: (10.1097/JTO.0b013e3181e2f4f5) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions